The TRAILBLAZER-ALZ 3 Clinical Research Study is evaluating the safety and effectiveness of an investigational drug for those at risk of developing symptoms of Alzheimer's disease.
The study involves people who have normal memory, thinking, mood and behavior patterns.
Participants are randomly assigned to one of two groups. They receive either the investigational drug or a placebo (a substance that looks like the investigational drug but contains no active ingredients). Those who receive placebo may have the option to receive the investigational drug at a later time.
If you qualify, participation can last as long as approximately 4.5 years, but will vary for each participant.